Revenue missed plan for the second straight quarter, so the company replaced the sales director, raised next year’s target by thirty percent, and signed a new CRM contract. Three of the biggest levers in commercial management, pulled in the same month. The pipeline looked much the same in April as it had in January, just with more red flags on a nicer dashboard.

Nobody had done anything unreasonable. These are the standard responses to disappointing revenue, and sometimes they’re the right ones. The question worth asking first is where the problem actually sits.

The sales team gets the invoice

Sales is usually the most visible function in a commercial organization, and visibility has a cost: when revenue disappoints, sales is the first place management looks, because sales activity can be measured, and measurement looks like control. Meetings held, quotations sent, pipeline value, all trackable in a way that “does the customer have an economically urgent problem” is not.

But a salesperson operates downstream of decisions they didn’t make: which segment the company entered, how the customer problem was defined, how the value proposition was framed, what evidence was assembled to support it, and whether the offer fits the way the customer actually buys. If those upstream choices are wrong, a strong sales team doesn’t fix them. It executes them faster, which mostly means generating more meetings that don’t close and a pipeline that looks busier without getting shorter.

When the expected growth doesn’t appear, the conclusion is often that the company hired the wrong person. Sometimes it did. But when a capable hire arrives with a strong network, gets an initial run of meetings from relationships built somewhere else, and then plateaus exactly where the last person did, the assignment deserves as much scrutiny as the individual. The qualification framework, the evidence base, and the offer they were selling were never rebuilt underneath them.

What the water sector keeps saying out loud

Water and wastewater technology makes this dynamic unusually visible. Utility procurement is conservative by design, and the vendors and sector specialists selling into it have become increasingly candid about exactly where deals stall. A June 2026 update from Isle Utilities, drawing partly on a Global Water Intelligence reader survey and discussion at the Global Water Summit in Madrid, names what it calls the “piloting valley of death”: technologies that pass a pilot on performance and still don’t get bought, because nobody built a route from a successful trial into an actual procurement decision. Sixty-five percent of the solution providers surveyed, not the utilities themselves, pointed to the same root obstacle: governments evaluating bids on upfront cost rather than lifecycle value, with no procurement mechanism built to reward a technology that costs more up front and less over twenty years.

More calls, stronger negotiation, and a revised commission plan don’t change how a utility’s procurement framework scores bids. It’s worth noting what Isle Utilities reports happens when the pathway is designed in advance rather than left to sales effort: around seventy percent of trials run through its Trial Reservoir model, which pre-commits each pilot to a defined commercial outcome before it starts, have progressed to contracts or commercial rollout, against an estimated general adoption rate of about twenty-five percent. Those figures are self-reported by the programme operator, not independently audited, so they’re best read as programme evidence rather than proof of causality. Still, they illustrate something real: technical success and a commercially executable path to adoption are not the same thing.

Which layer is actually broken

Before changing the sales team, it’s worth answering a short set of questions, because the wrong intervention wastes a year and a good salesperson’s reputation.

Do the accounts in the pipeline recognize an economically urgent problem, or an interesting one? Does the available evidence address the operational, financial, and procurement risks that actually block a decision, not just the technical ones? Can everyone on the team explain, in the same words, who uses the product, who evaluates it, who approves it, and who signs? Does interest actually progress through a repeatable sequence toward an order, or does it stall at the same stage every time? And, the most diagnostic question of the five: are several experienced, capable people failing at that same stage, in the same way, on unrelated accounts? One salesperson struggling might be a coaching problem. Three capable ones stalling at the identical point is a system reporting a defect.

What a good salesperson can fix, and what they can’t

A capable sales team improves prospecting, account selection, qualification discipline, negotiation, and follow-through. Those are real skills, and weak execution in any of them is a legitimate reason for a revenue miss: poor account planning, thin pipeline coverage, sloppy forecasting, a leader who doesn’t hold the team accountable. None of that should be waved away as “structural.”

What a sales team cannot do, no matter how good, is manufacture urgency in a customer who has none, invent evidence that satisfies a procurement process the company never studied, fix a market segment chosen for the wrong reasons, or build a channel that can carry demand nobody has generated yet. Those are design problems, and they get solved at the design layer or not at all.

Strong salespeople amplify a commercial system that works. Placed inside one that doesn’t, they often reach the same obstruction faster and document it more accurately. Before replacing the team again, inspect the system they were asked to sell through. The next CRM will record the problem. It won’t repair it.


The opening scene (revenue miss, sales-leader change, target increase, new CRM) is an illustrative composite drawn from recurring, documented commercial patterns; it does not describe a specific company.

Sources and verification note

Both sources below are published by Isle Utilities. They are not two independent sources corroborating each other, and are not presented as such. Isle Utilities is an active commercial party in this market: it operates the Trial Reservoir and Tech Ascend programmes discussed in the article. That is disclosed here rather than treated as neutral third-party evidence.

  • Dr Jo Burgess, Quarterly trends in technology piloting, Isle Utilities, 26 June 2026. Names the “piloting valley of death”; 65% of surveyed solution providers — explicitly not utilities — cite governments evaluating bids on upfront rather than lifecycle cost as the most significant obstacle to adoption. Limitation: the piece draws partly on a Global Water Intelligence reader survey and Global Water Summit discussion, but the underlying GWI survey instrument, sample size and methodology were not independently accessed; only Isle Utilities’ summary of it was reviewed.
  • 2025: The Year Water Innovation Finally Broke the Dam, Isle Utilities, 15 December 2025. The Trial Reservoir model reports roughly 70% of trials progressing to contracts or commercial rollout, against an estimated general adoption rate of about 25%. Limitation: both figures are self-reported by the programme operator. The 25% baseline has no disclosed independent source or methodology. The 70% figure is the operator’s own outcome data from a self-selected programme on the order of 20 cumulative trials, not a randomised or independently audited study. The comparison is not controlled and does not prove causality; selection effects and the additional support a curated programme provides may also contribute.

The article uses this evidence illustratively, in support of a broader argument about commercial systems, not as standalone statistical proof of it.